Latest Breaking News On - Health press limited - Page 1 : comparemela.com

(2) Press Release for European Medical and Trade Media Only BIAL announces the end of the licence agreement established in 2009. BIAL takes the lead for the marketing and distribution of Zebinix (eslicarbazepine acetate) in Europe. Eslicarbazepine acetate is a once-daily anti-epileptic used to treat epilepsy patients with focal seizures (partial-onset seizures) For over a decade, BIAL and Eisai have had an agreement in place for Eisai to market, promote, and distribute eslicarbazepine acetate in Europe. Following the end of this partnership, BIAL will take the lead for the ongoing marketing, promotion and distribution in Europe. This move reinforces its continued commitment to and ongoing investment in neurological conditions.

Susana vasconcelosAlmeida bastosBiochem biophysKostenloser wertpapierhandelChrissie hartgillMakara healthWorld health organizationHealth pressPress releaseEuropean medicalTrade mediaChief commercial officerVice presidentGlobal neurology business unitFostering epilepsy careLast accessed january